Durgical
EN
Open the app

Switching innate immunity off: IL-1Ra, IL-10, SOCS and A20

  • Process

Inflammation has built-in brakes; when a brake gene is missing, inflammation starts early in life and does not stop.

Updated

What it is

Innate responses must end once the threat is gone. Cells use soluble blockers (IL-1 receptor antagonist, decoy receptors), suppressive cytokines (IL-10, TGF-β) and intracellular brakes that switch signalling off (SOCS proteins on JAK–STAT, A20 on NF-κB). Single-gene loss of these brakes causes severe early inflammatory diseases, and the brakes themselves inspired drugs such as anakinra.

Key facts

  • Anakinra is a recombinant form of the body’s own IL-1 receptor antagonist.
  • Decoy receptors such as IL-1 receptor type II bind IL-1 without signalling.
  • Many brakes are induced by the inflammatory signal itself: a built-in negative feedback loop.

Step by step

  1. A microbe triggers TLRs and IL-1 receptors; NF-κB turns on inflammatory genes.
  2. The same signals induce their own brakes: A20, SOCS proteins and IL-10.
  3. A20 removes ubiquitin chains that keep the NF-κB pathway active, ending the signal.
  4. SOCS proteins bind JAKs and cytokine receptors and stop STAT signalling.
  5. IL-10 from macrophages and regulatory T cells lowers IL-12, TNF and costimulator expression.
  6. IL-1 receptor antagonist occupies the IL-1 receptor without signalling, competing with IL-1.

Brakes of innate immunity and what happens without them

BrakeHow it worksDisease when missing
IL-1 receptor antagonist (IL1RN)Blocks the IL-1 receptorDIRA: newborn pustular rash, osteomyelitis and periostitis; responds to anakinra
IL-10 or IL-10 receptorSuppresses macrophage and dendritic-cell activationVery early-onset inflammatory bowel disease in infancy
A20 (TNFAIP3)Deubiquitinase that ends NF-κB signallingHaploinsufficiency of A20: early-onset Behçet-like disease; common variants linked to lupus and RA
SOCS proteinsFeedback inhibitors of JAK–STATOveractive cytokine signalling (reported mainly as rare variants)
TGF-βSuppresses lymphocyte activation, promotes repairSevere multiorgan inflammation in animal models

Common traps

  • Anakinra is a foreign molecule that blocks IL-1: it is a recombinant copy of the body's own IL-1 receptor antagonist, which is why it corrects DIRA.
  • A20 is a kinase that switches NF-κB on: A20 is a deubiquitinase that switches NF-κB off, and losing one copy causes early Behçet-like disease.
  • Colitis in a young infant is always milk allergy or infection: very early-onset IBD suggests IL-10 or IL-10 receptor deficiency, curable by stem cell transplant.
  • Decoy receptors signal weakly: IL-1 receptor type II binds IL-1 without any signal, simply mopping it up.

Test yourself

Think of the answer, then tap the question to see it.

A newborn has a pustular rash and inflamed bones with high CRP and improves dramatically on anakinra. What is missing and why does the drug work?

The IL-1 receptor antagonist (DIRA); anakinra is the recombinant replacement, so it restores the missing brake on IL-1 signalling.

Why do inflammatory signals induce their own inhibitors, such as A20 and SOCS?

Negative feedback: the brake is made in proportion to the signal, so the response ends when the trigger falls instead of running on.

A baby develops severe colitis in the first months of life. Which cytokine pathway should be suspected?

IL-10 or its receptor: their loss causes very early-onset inflammatory bowel disease.

Add to my cards (3)

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Immune response (MedlinePlus, US National Library of Medicine, 2024); Crohn Disease (StatPearls (NCBI Bookshelf), 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.